The DOI matches its Crossref record; 140 of the 140 references it cites were found in a registry or an index.
Breast Cancer: Conventional Diagnosis and Treatment Modalities and Recent Patents and Technologies
Open accessAbstract
Breast cancer is the most prevalent cancer among women worldwide. However, increased survival is due to the dramatic advances in the screening methods, early diagnosis, and breakthroughs in treatments. Over the course of the last decade, many acquisitions have taken place in this critical field of research in the pharmaceutical industry. Advances in molecular biology and pharmacology aided in better understanding of breast cancer, enabling the design of smarter therapeutics able to target cancer and respond to its microenvironment efficiently. Patents and research papers investigating diagnosis and treatment strategies for breast cancer using novel technologies have been surveyed for the past 15 years. Various nanocarriers have been introduced to improve the therapeutic efficacy of anticancer drugs, including liposomes, polymeric micelles, quantum dots, nanoparticles, and dendrimers. This review provides an overview of breast cancer, conventional therapy, novel technologies in the management of breast cancer, and rational approaches for targeting breast cancer. Highlights: Breast cancer is the most common cancer in women worldwide. However, survival rates vary widely, optimistically heading toward a positive trend. Increased survival is due to the drastic shift in the screening methods, early diagnosis, and breakthroughs in treatments. Different strategies of breast cancer classification and staging have evolved over the years. Intrinsic (molecular) subtyping is essential in clinical trials and well understanding of the disease. Many novel technologies are being developed to detect distant metastases and recurrent disease as well as to assess response to breast cancer management. Intensive research efforts are actively ongoing to take novel breast cancer therapeutics to potential clinical application. Most of the recent research papers and patents discuss one of the following strategies: the development of new drug entities that specifically target the breast tumor cells; tailor designing a novel carrier system that can multitask and multifunction as a drug carrier, targeting vehicle and even as a diagnostic tool, direct conjugation of a therapeutic drug moiety with a targeting moiety, diagnostic moiety or pharmacokinetics altering moiety; or the use of innovative nontraditional approaches such as genetic engineering, stem cells, or vaccinations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
Paik, S., Shak, S., Tang, G., Kim, C., Baker, J., Cronin, M., Baehner, F. L., Walker, M. G., Watson, D., Park, T., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa041588 · Cited by 6,277
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Drug delivery and nanoparticles: Applications and hazards
de Jong (2008) · International Journal of Nanomedicine · doi:10.2147/ijn.s596 · Cited by 3,848
PLGA-based nanoparticles: An overview of biomedical applications
Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Préat, V. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.01.043 · Cited by 3,806
Nanomaterials and nanoparticles: Sources and toxicity
Buzea, C., Pacheco, I. I., & Robbie, K. (2007) · Biointerphases · doi:10.1116/1.2815690 · Cited by 3,789
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Senn, H.-J., Albain, K. S., André, F., Bergh, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt303 · Cited by 3,746
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Nanoparticles in cancer therapy and diagnosis
Brigger, I., Dubernet, C., & Couvreur, P. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00044-3 · Cited by 3,039
Therapeutic Nanoparticles for Drug Delivery in Cancer
Cho, K., Wang, X., Nie, S., Chen, Z. (., & Shin, D. M. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1441 · Cited by 2,920
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Aebi, S., Davidson, T., Gruber, G., & Castiglione, M. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq159 · Cited by 2,842
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Keefe, A. D., Pai, S., & Ellington, A. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3141 · Cited by 2,289
Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2012) · The Lancet · doi:10.1016/s0140-6736(11)61625-5 · Cited by 2,089
Davies, C., Pan, H., Godwin, J., Gray, R., Arriagada, R., Raina, V., Abraham, M., Alencar, V. H. M., Badran, A., Bonfill, X., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61963-1 · Cited by 2,044
Applications of Carbon Nanotubes in Drug Delivery
Kaur, J., Gill, G. S., & Jeet, K. (2019) · Characterization and Biology of Nanomaterials for Drug Delivery · doi:10.1016/b978-0-12-814031-4.00005-2 · Cited by 2,019
Polymer conjugates as anticancer nanomedicines
Duncan, R. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1958 · Cited by 1,962
Finn, R. S., Crown, J. P., Lang, I., Boer, K., Bondarenko, I. M., Kulyk, S. O., Ettl, J., Patel, R., Pinter, T., Schmidt, M., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71159-3 · Cited by 1,900
Delivery materials for siRNA therapeutics
Kanasty, R., Dorkin, J. R., Vegas, A., & Anderson, D. (2013) · Nature Materials · doi:10.1038/nmat3765 · Cited by 1,800
O’Brien, M. E. R., Wigler, N., Inbar, M., Rosso, R., Grischke, E., Santoro, A., Catane, R., Kieback, D. G., Tomczak, P., Ackland, S. P., et al. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh097 · Cited by 1,738
Targeted drug delivery via the folate receptor
Sudimack, J., & Lee, R. J. (2000) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(99)00062-9 · Cited by 1,474
Drug targeting to tumors: Principles, pitfalls and (pre-) clinical progress
Lammers, T., Kiessling, F., Hennink, W. E., & Storm, G. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.09.063 · Cited by 1,324
Buyse, M., Loi, S., van't Veer, L., Viale, G., Delorenzi, M., Glas, A. M., Saghatchian d'Assignies, M., Bergh, J., Lidereau, R., Ellis, P., et al. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj329 · Cited by 1,238
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
PEG-modified gold nanorods with a stealth character for in vivo applications
Niidome, T., Yamagata, M., Okamoto, Y., Akiyama, Y., Takahashi, H., Kawano, T., Katayama, Y., & Niidome, Y. (2006) · Journal of Controlled Release · doi:10.1016/j.jconrel.2006.06.017 · Cited by 1,200
Amphiphilic block copolymers for drug delivery
Adams, M. L., Lavasanifar, A., & Kwon, G. S. (2003) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10397 · Cited by 1,078
Design of Liposomes for Enhanced Local Release of Drugs by Hyperthermia
Yatvin, M. B., Weinstein, J. N., Dennis, W. H., & Blumenthal, R. (1978) · Science · doi:10.1126/science.364652 · Cited by 956
Bast, R. C., Ravdin, P., Hayes, D. F., Bates, S., Fritsche, H., Jessup, J. M., Kemeny, N., Locker, G. Y., Mennel, R. G., & Somerfield, M. R. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1865 · Cited by 879
Targeted Delivery of Amphotericin B to Cells by Using Functionalized Carbon Nanotubes
Wu, W., Wieckowski, S., Pastorin, G., Benincasa, M., Klumpp, C., Briand, J., Gennaro, R., Prato, M., & Bianco, A. (2005) · Angewandte Chemie International Edition · doi:10.1002/anie.200501613 · Cited by 644
Stealth Me. PEG‐PLA Nanoparticles Avoid Uptake by the Mononuclear Phagocytes System
Bazile, D., Prud'homme, C., Bassoullet, M., Marlard, M., Spenlehauer, G., & Veillard, M. (1995) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600840420 · Cited by 635
Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs · doi:10.1007/s10637-014-0120-7 · Cited by 577
Weigelt, B., Horlings, H., Kreike, B., Hayes, M., Hauptmann, M., Wessels, L., de Jong, D., Van de Vijver, M., Veer, L. V., & Peterse, J. (2008) · The Journal of Pathology · doi:10.1002/path.2407 · Cited by 562
Tumour-targeted nanomedicines: principles and practice
Lammers, T., Hennink, W. E., & Storm, G. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604483 · Cited by 542
Understanding breast cancer risk - where do we stand in 2005?
Dumitrescu, R. G., & Cotarla, I. (2005) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2005.tb00350.x · Cited by 502
Giordano, S. H., Buzdar, A. U., & Hortobagyi, G. N. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00013 · Cited by 490
KUHN, W., HARGITAY, B., KATCHALSKY, A., & EISENBERG, H. (1950) · Nature · doi:10.1038/165514a0 · Cited by 490
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Senkus, E., Kyriakides, S., Penault-Llorca, F., Poortmans, P., Thompson, A., Zackrisson, S., & Cardoso, F. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt284 · Cited by 479
Histological, molecular and functional subtypes of breast cancers
Malhotra, G. K., Zhao, X., Band, H., & Band, V. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.10.13879 · Cited by 475
Gnant, M., Mlineritsch, B., Stoeger, H., Luschin-Ebengreuth, G., Heck, D., Menzel, C., Jakesz, R., Seifert, M., Hubalek, M., Pristauz, G., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70122-x · Cited by 472
Joensuu, H., Bono, P., Kataja, V., Alanko, T., Kokko, R., Asola, R., Utriainen, T., Turpeenniemi-Hujanen, T., Jyrkkiö, S., Möykkynen, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.4577 · Cited by 458
Lemieux, J., Maunsell, E., & Provencher, L. (2008) · Psycho-Oncology · doi:10.1002/pon.1245 · Cited by 427
(1990) · PubMed · Cited by 398
Reyes-Reyes, E. M., Teng, Y., & Bates, P. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0920 · Cited by 383
Invasive lobular carcinoma of the breast: morphology, biomarkers and ’omics
Reed, A. E. M., Kutasovic, J. R., Lakhani, S. R., & Simpson, P. T. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0519-x · Cited by 373
Bisphosphonates for breast cancer
Pavlakis, N., & Stockler, M. (2002) · The Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003474 · Cited by 360
Circulating microRNAs in breast cancer and healthy subjects
Zhu, W., Qin, W., Atasoy, U., & Sauter, E. R. (2009) · BMC Research Notes · doi:10.1186/1756-0500-2-89 · Cited by 359
Targeted epidermal growth factor receptor nanoparticle bioconjugates for breast cancer therapy
Acharya, S., Dilnawaz, F., & Sahoo, S. K. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.07.008 · Cited by 333
Protocol for the Examination of Specimens From Patients With Invasive Carcinoma of the Breast
Lester, S. C., Bose, S., Chen, Y.-Y., Connolly, J. L., de Baca, M. E., Fitzgibbons, P. L., Hayes, D. F., Kleer, C., O'Malley, F. P., Page, D. L., et al. (2009) · Archives of Pathology & Laboratory Medicine · doi:10.5858/133.10.1515 · Cited by 302
Hwang, D. W., Ko, H. Y., Lee, J. H., Kang, H., Ryu, S. H., Song, I. C., Lee, D. S., & Kim, S. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.109.069880 · Cited by 293
MAEDA, H. (2012) · Proceedings of the Japan Academy, Series B · doi:10.2183/pjab.88.53 · Cited by 291
Liposomes as carriers of enzymes or drugs: a new approach to the treatment of storage diseases
Gregoriadis, G., & Ryman, B. E. (1971) · Biochemical Journal · doi:10.1042/bj1240058p · Cited by 286
Kerlikowske, K., Hubbard, R. A., Miglioretti, D. L., Geller, B. M., Yankaskas, B. C., Lehman, C. D., Taplin, S. H., Sickles, E. A., & for the Breast Cancer Surveillance Consortium (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-8-201110180-00005 · Cited by 268
The effect of poloxamer 188 on nanoparticle morphology, size, cancer cell uptake, and cytotoxicity
Yan, F., Zhang, C., Zheng, Y., Mei, L., Tang, L., Song, C., Sun, H., & Huang, L. (2010) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2009.05.004 · Cited by 238
Duggan, S. T., & Keating, G. M. (2011) · Drugs · doi:10.2165/11207510-000000000-00000 · Cited by 234
Recent Trends in Multifunctional Liposomal Nanocarriers for Enhanced Tumor Targeting
Perche, F., & Torchilin, V. P. (2013) · Journal of Drug Delivery · doi:10.1155/2013/705265 · Cited by 230
Liu, Y., Wang, W., Yang, J., Zhou, C., & Sun, J. (2013) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2013.07.021 · Cited by 223
Cardiotoxicity Profile of Trastuzumab
Ewer, S. M., & Ewer, M. S. (2008) · Drug Safety · doi:10.2165/00002018-200831060-00002 · Cited by 206
In vitro antitumor activity of methotrexate via pH-sensitive chitosan nanoparticles
Nogueira, D. R., Tavano, L., Mitjans, M., Pérez, L., Infante, M. R., & Vinardell, M. P. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.01.005 · Cited by 205
Fürstenberger, G., von Moos, R., Lucas, R., Thürlimann, B., Senn, H.-J., Hamacher, J., & Boneberg, E.-M. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6602952 · Cited by 205
Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS
James, N. D., Coker, R. J., Tomlinson, D., Harris, J. R. W., Gompels, M., Pinching, A. J., & Stewart, J. S. W. (1994) · Clinical Oncology · doi:10.1016/s0936-6555(05)80269-9 · Cited by 205
Novel HER2 Aptamer Selectively Delivers Cytotoxic Drug to HER2-positive Breast Cancer Cells in Vitro
Liu, Z., Duan, J.-H., Song, Y.-M., Ma, J., Wang, F.-D., Lu, X., & Yang, X.-D. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-148 · Cited by 193
AS1411 aptamer tagged PLGA‐lecithin‐PEG nanoparticles for tumor cell targeting and drug delivery
Aravind, A., Jeyamohan, P., Nair, R., Veeranarayanan, S., Nagaoka, Y., Yoshida, Y., Maekawa, T., & Kumar, D. S. (2012) · Biotechnology and Bioengineering · doi:10.1002/bit.24558 · Cited by 191
Vail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., & Working, P. K. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.002 · Cited by 187
Heyn, H., Carmona, F. J., Gómez, A., Ferreira, H. J., Bell, J. T., Sayols, S., Ward, K. J., Stefánsson, Ó. A., Morán, S., Sandoval, J., et al. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs321 · Cited by 174
Prinzen, L., Miserus, R.-J. J. H. M., Dirksen, A., Hackeng, T. M., Deckers, N., Bitsch, N. J., Megens, Douma, K., Heemskerk, J. W., Kooi, M. E., et al. (2007) · Nano Letters · doi:10.1021/nl062226r · Cited by 168
Breast Cancer: A Review for the General Surgeon
Matsen, C. B., & Neumayer, L. A. (2013) · JAMA Surgery · doi:10.1001/jamasurg.2013.3393 · Cited by 167
Minireview: Basal-Like Breast Cancer: From Molecular Profiles to Targeted Therapies
Toft, D. J., & Cryns, V. L. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0164 · Cited by 161
Inic, Z., Zegarac, M., Inic, M., Markovic, I., Kozomara, Z., Djurisic, I., Inic, I., Pupic, G., & Jancic, S. (2014) · Clinical Medicine Insights: Oncology · doi:10.4137/cmo.s18006 · Cited by 160
Gómez-Raposo, C., Zambrana Tévar, F., Sereno Moyano, M., López Gómez, M., & Casado, E. (2010) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.02.002 · Cited by 159
Bioresponsive matrices in drug delivery
You, J., Almeda, D., Ye, G. J. C., & Auguste, D. T. (2010) · Journal of Biological Engineering · doi:10.1186/1754-1611-4-15 · Cited by 141
Barth, B. M., Sharma, R., Altınoğlu, E. İ., Morgan, T. T., Shanmugavelandy, S. S., Kaiser, J. M., McGovern, C. O., Matters, G. L., Smith, J. P., KESTER, M. A., et al. (2010) · ACS Nano · doi:10.1021/nn901297q · Cited by 136
Advances in Novel Drug Delivery Strategies for Breast Cancer Therapy
Dhankhar, R., Vyas, S. P., Jain, A., Arora, S., Rath, G., & Goyal, A. K. (2010) · Artificial Cells Blood Substitutes and Biotechnology · doi:10.3109/10731199.2010.494578 · Cited by 128
Novel nanomedicine-based MRI contrast agents for gynecological malignancies
Mody, V. V., Nounou, M. I., & Bikram, M. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.04.020 · Cited by 128
Self-citationNucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery
Wu, J., Song, C., Jiang, C., Shen, X., Qiao, Q., & Hu, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300686g · Cited by 125
Lale, S. V., Girija, A. R., Aravind, A., Kumar, D. S., & Koul, V. (2014) · Biomacromolecules · doi:10.1021/bm5001263 · Cited by 125
Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin™ for active targeting
Bossy-Nobs, L., Buchegger, F., Gurny, R., & Allémann, É. (2004) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.04.006 · Cited by 117
Leptin–STAT3–G9a Signaling Promotes Obesity-Mediated Breast Cancer Progression
Chang, C.-C., Wu, M., Yang, J.-Y., Camarillo, I. G., & Chang, C.-J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-3076 · Cited by 117
A Hypothesis of the Origin of Human Breast Cancer from the Terminal Ductal Lobular Unit
WELLINGS, S. R. (1980) · Pathology - Research and Practice · doi:10.1016/s0344-0338(80)80248-2 · Cited by 114
Callahan, R. D., & Hurvitz, S. A. (2010) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e3283414e87 · Cited by 114
Palbociclib: an evidence-based review of its potential in the treatment of breast cancer
Traina, T. A., Cadoo, K. A., & Gucalp, A. (2014) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s46725 · Cited by 113
Gonzalez-Angulo, A. M., Akçakanat, A., Liu, S., Green, M. C., Murray, J. L., Chen, H., Palla, S. L., Koenig, K. B., Brewster, A. M., Valero, V., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu124 · Cited by 110
WGA-grafted PLGA-nanospheres: preparation and association with Caco-2 single cells
Weissenböck, A., Wirth, M., & Gabor, F. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.025 · Cited by 109
O'Sullivan, C. C., Bradbury, I., Campbell, C., Spielmann, M., Perez, E. A., Joensuu, H., Costantino, J. P., Delaloge, S., Rastogi, P., Zardavas, D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.60.8620 · Cited by 108
Wang, K., Yao, H., Meng, Y., Wang, Y., Yan, X., & Huang, R. (2015) · Acta Biomaterialia · doi:10.1016/j.actbio.2015.01.002 · Cited by 107
Mohammadi, M., Salmasi, Z., Hashemi, M., Mosaffa, F., Abnous, K., & Ramezani, M. (2015) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2015.02.031 · Cited by 101
Neal, L., Sandhu, N. P., Hieken, T. J., Glazebrook, K. N., Bride, M. B. M., Dilaveri, C. A., Wahner‐Roedler, D. L., Ghosh, K., & Visscher, D. W. (2014) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2014.02.004 · Cited by 97
Particle Shape: A New Design Parameter for Passive Targeting In Splenotropic Drug Delivery
Devarajan, P. V., Jindal, A. B., Patil, R. R., Mulla, F., Gaikwad, R. V., & Samad, A. (2010) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.22052 · Cited by 96
Design strategies for fluorescent biodegradable polymeric biomaterials
Zhang, Y., & Yang, J. Y. (2012) · Journal of Materials Chemistry B · doi:10.1039/c2tb00071g · Cited by 94
Sensitivity of HER-2/neu Antibodies in Archival Tissue Samples of Invasive Breast Carcinomas
Gancberg, D., Lespagnard, L., Rouas, G., Paesmans, M., Piccart, M. J., Leo, A. D., Nogaret, J., Hertens, D., Verhest, A. P., & Larsimont, D. (2000) · American Journal of Clinical Pathology · doi:10.1309/0f58-0grx-fk4r-a6va · Cited by 91
Beyond trastuzumab: novel therapeutic strategies in HER2-positive metastatic breast cancer
Tsang, R. Y., & Finn, R. S. (2012) · British Journal of Cancer · doi:10.1038/bjc.2011.516 · Cited by 90
Pegylated liposomal doxorubicin in the treatment of cancers of the breast and ovary
Markman, M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.11.1469 · Cited by 82
Nanoshells for Photothermal Cancer Therapy
Morton, J. G., Day, E. S., Halas, N. J., & West, J. L. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-609-2_7 · Cited by 81
Dowsett, M., Stein, R. C., & Coombes, R. C. (1992) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/0960-0760(92)90201-s · Cited by 81
Targeting Breast Cancer with CDK Inhibitors
Mayer, E. L. (2015) · Current Oncology Reports · doi:10.1007/s11912-015-0443-3 · Cited by 79
Cellular delivery of PEGylated PLGA nanoparticles
Pamujula, S., Hazari, S., Bolden, G., Graves, R. A., Chinta, D. D., Dash, S., Kishore, V., & Mandal, T. K. (2011) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.2011.01376.x · Cited by 78
Turetschek, K., Roberts, T. P. L., Floyd, E., et al. (2001) · Journal of Magnetic Resonance Imaging · doi:10.1002/jmri.1126 · Cited by 76
Breast Cancer Screening and Biomarkers
Brooks, M. N. (2008) · Methods in molecular biology · doi:10.1007/978-1-60327-492-0_13 · Cited by 72
Recent advances in breast MRI and MRS
Sinha, S., & Sinha, U. S. (2008) · NMR in Biomedicine · doi:10.1002/nbm.1270 · Cited by 70
Swain, S. M., Im, Y., Im, S., Chan, V. F., Miles, D. W., Knott, A., Clark, E., Ross, G. A., & Baselga, J. M. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0033 · Cited by 69
Hoekstra, D., & Scherphof, G. L. (1979) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(79)90357-2 · Cited by 68
Wang, L., Peng, C., Chen, C., & Li, Y. (2015) · Breast Cancer Research and Treatment · doi:10.1007/s10549-015-3363-x · Cited by 67
Kirby, C. J., & Gregoriadis, G. C. (1980) · Life Sciences · doi:10.1016/0024-3205(80)90388-4 · Cited by 62
Önyüksel, H., MOHANTY, P., & RUBINSTEIN, I. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.08.024 · Cited by 62
Development of viral nanoparticles for efficient intracellular delivery
Wu, Z., Chen, K., Yıldız, İ., Dirksen, A., Fischer, R., Dawson, P. E., & Steinmetz, N. F. (2012) · Nanoscale · doi:10.1039/c2nr30366c · Cited by 61
Zhou, W., Zhou, Y., Wu, J., Liu, Z., Zhao, H., Liu, J., & Ding, J. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.839683 · Cited by 55
Hoch, U., Staschen, C., Johnson, R. K., & Eldon, M. A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2577-7 · Cited by 55
A 2D mechanistic model of breast ductal carcinoma in situ (DCIS) morphology and progression
Norton, K., Wininger, M., Bhanot, G., Ganesan, S., Barnard, N., & Shinbrot, T. (2009) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2009.11.024 · Cited by 54
mTOR inhibitors in the treatment of breast cancer.
Vinayak, S., & Carlson, R. W. (2013) · PubMed · Cited by 52
Zhang, P., Ling, G., Sun, J., Zhang, T., Yuan, Y., Sun, Y., Wang, Z., & He, Z. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.04.022 · Cited by 51
Yardley, D. A. (2013) · Breast Cancer Basic and Clinical Research · doi:10.4137/bcbcr.s10071 · Cited by 50
Chen, J., Li, S., Shen, Q., He, H., & Zhang, Y. (2011) · Drug Development and Industrial Pharmacy · doi:10.3109/03639045.2011.575162 · Cited by 48
Inorganic Nanoparticles for Predictive Oncology of Breast Cancer
Yezhelyev, M. V., Yacoub, R., & O’Regan, R. M. (2008) · Nanomedicine · doi:10.2217/17435889.4.1.83 · Cited by 48
The prevention, detection, and management of breast cancer
Houssami, N., Cuzick, J. M., & Dixon, J. M. (2006) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00208.x · Cited by 46
Shao, N., Wang, S., Chen, Y., Xu, X., Zhang, Y., Zhang, Y., & Lin, Y. (2012) · The Breast · doi:10.1016/j.breast.2012.03.011 · Cited by 46
Hapuarachchige, S., Zhu, W., Katō, Y., & Artemov, D. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.11.075 · Cited by 45
Molecular drivers of lobular carcinoma in situ
Logan, G. J., Dabbs, D. J., Lucas, P. C., Jankowitz, R. C., Brown, D. D., Clark, B. Z., Oesterreich, S., & McAuliffe, P. F. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0580-5 · Cited by 44
Fine needle aspiration for evaluation of breast masses
Chaiwun, B., & Thorner, P. S. (2007) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0b013e328011f9ae · Cited by 44
Bisphosphonates in breast cancer
Mathew, A., & Brufsky, A. (2014) · International Journal of Cancer · doi:10.1002/ijc.28965 · Cited by 41
eIF3c: A potential therapeutic target for cancer
Emmanuel, R., Weinstein, S., Landesman‐Milo, D., & Peer, D. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.04.026 · Cited by 41
Clinical proteomics and breast cancer
Zeidan, B. A., Townsend, P. A., Garbis, S. D., Copson, E., & Cutress, R. (2015) · The Surgeon · doi:10.1016/j.surge.2014.12.003 · Cited by 40
Papadimitriou, K., Papademetriou, K., Ardavanis, A. S., & Kountourakis, P. (2010) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2010.02.03.8 · Cited by 38
Hormonal therapies in young breast cancer patients: when, what and for how long?
Christinat, A., Lascio, S. D., & Pagani, O. (2013) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2072-1439.2013.05.25 · Cited by 37
Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer
Mancini, P., Angeloni, A., Risi, E., Orsi, E., & Mezi, S. (2014) · Cancers · doi:10.3390/cancers6042187 · Cited by 36
Harnessing RNAi nanomedicine for precision therapy
Peer, D. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-5 · Cited by 35
Adjuvant endocrine therapy for premenopausal women with breast cancer
Puhalla, S., Brufsky, A., & Davidson, N. E. (2009) · The Breast · doi:10.1016/s0960-9776(09)70286-3 · Cited by 34
Ca2+-binding protein S100A11: A novel diagnostic marker for breast carcinoma
Fan (2010) · Oncology Reports · doi:10.3892/or_00000764 · Cited by 32
Kohshour, M. O., Mirzaie, S., Zeinali, M., Amin, M., Hakhamaneshi, M. S., Jalili, A., Mosaveri, N., & Jamalan, M. (2013) · Chemical Biology & Drug Design · doi:10.1111/cbdd.12244 · Cited by 28
Economopoulos, V., Chen, Y.-H., McFadden, C. D., & Foster, P. J. (2013) · Translational Oncology · doi:10.1593/tlo.13121 · Cited by 25
Current Major Cancer Targets for Nanoparticle Systems
Wesselinova, D. W. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911794328484 · Cited by 22
Autoantibody response to a novel tumor-associated antigen p90/CIP2A in breast cancer immunodiagnosis
Liu, X., Chai, Y., Li, J., Ren, P., Liu, M., Dai, L., Qian, W., Li, W., & Zhang, J.-Y. (2014) · Tumor Biology · doi:10.1007/s13277-013-1350-6 · Cited by 21
Liu, C. W., & Lin, L. (2013) · Journal of drug targeting · doi:10.3109/1061186x.2013.811511 · Cited by 20
The Papyrus Ebers. Translated from the German Version.
(1932) · JAMA · doi:10.1001/jama.1932.02730360064036 · Cited by 20
Drug News and Trial Developments
(1995) · Aids Patient Care · doi:10.1089/apc.1995.9.306 · Cited by 17
Muggia, F. M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.811 · Cited by 16
Sanchez, G. M., & Meltzer, E. S. (2012) · Lockwood Press eBooks · doi:10.5913/2012017 · Cited by 10
(1995) · PubMed · Cited by 8
Cited by
Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer
Ye, F., Dewanjee, S., Li, Y., Jha, N. K., Chen, Z.-S., Kumar, A., Vishakha, Behl, T., Jha, S. K., & Tang, H. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01805-y · Cited by 554
[Retracted] Global Increase in Breast Cancer Incidence: Risk Factors and Preventive Measures
Kashyap, D., Pal, D., Sharma, R., Garg, V. K., Goel, N., Koundal, D., Zaguia, A., Koundal, S., & Belay, A. (2022) · BioMed Research International · doi:10.1155/2022/9605439 · Cited by 529
RetractedArab-Bafrani, Z., Zabihi, E., Jafari, S. M., Khoshbin-Khoshnazar, A., Mousavi, E., Khalili, M., & Babaei, A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120828 · Cited by 39
Metadata
- Authors
- Nounou, M. I., ElAmrawy, F., Ahmed, N., Abdelraouf, K., Goda, S., & Syed-Sha-Qhattal, H.
- Venue
- Breast Cancer: Basic and Clinical Research
- Publisher
- SAGE Publications
- Published
- 2015-01
- Volume
- 9s2
- Issue
- Suppl 2
- Pages
- BCBCR.S29420
- ISSN
- 1178-2234 (ISSN-L)
- OpenAlex
- W2110361622
- Cited by
- 364
- References
- 140
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.